Evaluation of neuropathy in patients on suramin treatment

Muscle & Nerve
B SolivenM J Ratain

Abstract

Suramin, a promising chemotherapeutic agent, causes a dose-limiting sensorimotor polyneuropathy. We undertook a phase 1 study of suramin that included serial neurologic and electrophysiologic examinations as part of the safety evaluation. We found that 6 of 41 (15%) patients developed suramin-induced demyelinating neuropathy which resembled Guillain-Barre syndrome clinically. There was 1 asymptomatic patient with electrophysiologic abnormalities suggestive of a demyelinating neuropathy. In addition, 1 patient with mild axonal neuropathy at baseline had deterioration of his symptoms during suramin treatment. Four asymptomatic patients developed electrophysiologic findings suggestive of a mild axonal neuropathy. We conclude that: (1) serial electrophysiologic monitoring is helpful for early detection of suramin-induced neuropathy; and (2) fixed dosing schedule of suramin without adaptive control does not lead to an increased incidence of demyelinating neuropathy when compared to adaptively controlled dosing schedules.

References

Jan 1, 1978·Advances in Pharmacology and Chemotherapy·F Hawking
Jun 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C MyersM M Uhrich
Apr 1, 1992·Journal of the National Cancer Institute·C W TaylorS E Salmon
Jun 1, 1990·Neurology·R V La RoccaM C Dalakas
Jan 1, 1990·Annals of Neurology·A K Asbury, D R Cornblath
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A SteinC E Myers
Sep 1, 1985·Brain : a Journal of Neurology·J M Jacobs, F R Costa-Jussà
Jul 1, 1987·Journal of Cellular Physiology·R J CoffeyH L Moses
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A EisenbergerS C Jacobs
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K KobayashiM J Ratain
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K KellyM Schwartz
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J BittonM R Cooper
Aug 1, 1994·Annals of Neurology·J W RussellJ L Podratz
Apr 21, 1993·Journal of the National Cancer Institute·M A EisenbergerM J Egorin

❮ Previous
Next ❯

Citations

Sep 28, 2002·Current Opinion in Neurology·Amanda C Peltier, James W Russell
Dec 11, 1999·Current Opinion in Neurology·A J Windebank
Jun 22, 2000·The Prostate·B S SlusherP F Jackson
Jan 1, 2003·Current Neurology and Neuroscience Reports·Louis H Weimer
Oct 27, 2004·Expert Opinion on Drug Safety·Guido Cavaletti, Paola Marmiroli
Aug 28, 2003·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·T BachmannG Seidel
Nov 7, 1998·Cancer Treatment Reviews·A J Dowling, I F Tannock
Apr 15, 2003·Neurologic Clinics·Hannah R Briemberg, Anthony A Amato

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.